“Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s376. doi:10.25251/skin.8.supp.376.